Latest News and Press Releases
Want to stay updated on the latest news?
-
GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities Phase 2 pilot study demonstrated an Overall Response Rate of 78% PORTLAND, Ore., June 15, 2015 (GLOBE NEWSWIRE) --...
-
PORTLAND, Ore., May 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
-
GALE-301 demonstrates promising preliminary efficacy data with a projected 78% reduction in relative risk of recurrence in the 1000 mcg dose cohort Leica Biosystem's Bond Oracle HER2...
-
PORTLAND, Ore., May 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
-
Completed enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial Commercial programs continue on track Abstral® (fentanyl) Sublingual...
-
PORTLAND, Ore., April 23, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...
-
PORTLAND, Ore., April 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
-
PORTLAND, Ore., April 10, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
-
PORTLAND, Ore., March 31, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
-
PORTLAND, Ore., March 26, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...